Cancer Research and Treatment

Original Article

Poor Preoperative Glycemic Control Is Associated with Dismal Prognosis after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Korean Multicenter Study: Sung Gu Kang, Eu Chang Hwang, Seung Il Jung, Ho Song Yu, Ho Seok Chung, Taek Won Kang, Dong Deuk Kwon, Jun Eul Hwang, Jun Seok Kim, Joon Hwa Noh, Jae Hyung You, Myung Ki Kim, Tae Hoon Oh, Ill Young Seo, Seung Baik, Chul-Sung Kim, Seok Ho Kang, Jun Cheon; Cancer Res Treat. 2016;48(4):1293-1301. Published online March 23, 2016; DOI: https://doi.org/10.4143/crt.2016.021

Purpose
The purpose of this study is to evaluate the effect of diabetes mellitus (DM) and preoperative glycemic control on prognosis in Korean patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU). Materials and Methods A total of 566 patients who underwent RNU at six institutions between 2004 and 2014 were reviewed retrospectively. Kaplan-Meier and Cox regression analyses were performed to assess the association between DM, preoperative glycemic control, and recurrence-free, cancer-specific, and overall survival.
Results
The median follow-up period was 33.8 months (interquartile range, 41.4 months). A total of 135 patients (23.8%) had DM and 67 patients (11.8%) had poor preoperative glycemic control. Patients with poor preoperative glycemic control had significantly shorter median recurrence-free, cancer-specific, and overall survival than patients with good preoperative glycemic control and non-diabetics (all, p=0.001). In multivariable Cox regression analysis, DM with poor preoperative glycemic control showed association with worse recurrence-free survival (hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.31 to 3.90; p=0.003), cancer-specific survival (HR, 2.96; 95% CI, 1.80 to 4.87; p=0.001), and overall survival (HR, 2.13; 95% CI, 1.40 to 3.22; p=0.001). Conclusion Diabetic UTUC patients with poor preoperative glycemic control had significantly worse oncologic outcomes than diabetic UTUC patients with good preoperative glycemic control and non-diabetics. Further investigation is needed to elucidate the exact mechanism underlying the impact of glycemic control on UTUC treatment outcome.

Citations

Citations to this article as recorded by

Development and validation of a prediction model for early recurrence in upper tract urothelial carcinoma treated with radical nephroureterectomy
Yi-Ju Chou, Hao-Lun Luo, Hung-Jen Wang, Steven K. Huang, Yu-Che Hsieh, Wen-Jeng Wu, Ching-Chia Li, Han-Yu Weng, Ta-Yao Tai, Chao-Hsiang Chang, Hsi-Chin Wu, Po-Hung Lin, Jacob See-Tong Pang, Chung-Hsin Chen, Jian-Hua Hong, Jen-Shu Tseng, Marcelo Chen, I-Hs
BMC Cancer.2025;[Epub] CrossRef
Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians
Laura Ashley, Saifuddin Kassim, Ian Kellar, Lisa Kidd, Frances Mair, Mike Matthews, Mollie Price, Daniel Swinson, Johanna Taylor, Galina Velikova, Jonathan Wadsley
BMJ Open.2022; 12(2): e060402. CrossRef
Annular-shaped stenosis in the ureter: Caution should be taken
Jie Ming, Yue Wang, Ziliang Su, Chunyang Wang
Urologic Oncology: Seminars and Original Investigations.2022; 40(6): 274.e7. CrossRef
Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis
Suping Ling, Michael Sweeting, Francesco Zaccardi, David Adlam, Umesh T. Kadam
BMC Cancer.2022;[Epub] CrossRef
Malnutrition management of hospitalized patients with diabetes/hyperglycemia and cancer cachexia
Rosa Burgos Peláez, José Pablo Suárez Llanos, Jose Manuel García Almeida, Pilar Matía Martín, Samara Palma Milla, Alejandro Sanz Paris, Ana Zugasti Murillo, Ana Artero-Fullana, Alfonso Calañas Continente, M.ª Jesús Chinchetru, Katherine García Malpartida,
Nutrición Hospitalaria.2022;[Epub] CrossRef
The Impact of Diabetes on the Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
Xiaoshuai Gao, Liang Zhou, Jianzhong Ai, Wei Wang, Xingpeng Di, Liao Peng, Banghua Liao, Xi Jin, Hong Li, Kunjie Wang
Frontiers in Oncology.2021;[Epub] CrossRef
The Prognostic Value of Lymphovascular Invasion in Patients With Upper Tract Urinary Carcinoma After Surgery: An Updated Systematic Review and Meta-Analysis
Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Jun Yuan, Yejun Feng
Frontiers in Oncology.2020;[Epub] CrossRef
The impact of preoperative glycated hemoglobin levels on outcomes in oral squamous cell carcinoma
Ze Yun Tay, Huang‐Kai Kao, Kuang‐Hsu Lien, Shao‐Yu Hung, Yenlin Huang, Ngan‐Ming Tsang, Kai‐Ping Chang
Oral Diseases.2020; 26(7): 1449. CrossRef

11,142 View
121 Download
9 Web of Science
8 Crossref

Case Report

Multimodal Treatment of Primary Extraskeletal Ewing's Sarcoma of the Chest Wall: Report of 2 Cases: Woo Surng Lee, Yo Han Kim, Hyun Keun Chee, Jae Joon Hwang, Jun Seok Kim, Song Am Lee, Eun Gu Hwang, Yo Han Cho, Gyu Rak Chon; Cancer Res Treat. 2009;41(2):108-112. Published online June 30, 2009; DOI: https://doi.org/10.4143/crt.2009.41.2.108

Abstract PDF PubReader ePub

Extraskeletal Ewing's sarcoma (EES) is a type of Ewing's sarcoma that arises in soft tissue and is now regarded as a member of a family of small round cell neoplasms of bone and soft tissue, including primitive neuroectodermal tumors (PNETs). EES occurs predominantly in adolescents and young adults between the ages of 10 and 30 years. The disease follows an aggressive course with a high recurrence rate. The presence of a distant metastasis is also common. EES arises in the soft tissue of either the trunk or extremities. We recently experienced two cases of EES that occurred in the chest wall. The two patients underwent wide resection and combined radiochemotherapy. There was no evidence of disease 30 and 22 months, respectively, after surgery. Although extremely rare, EES should be considered in the differential diagnosis of chest wall tumors. We report two cases of EES with a brief review of the literature.

Citations

Citations to this article as recorded by

Large retroperitoneal extraskeletal Ewing’s sarcoma with renal pedicle invasion: a case report
Shu-Yu Wu, Chun-Kai Hsu, Chung-Tai Yue, Yao-Chou Tsai
BMC Urology.2023;[Epub] CrossRef
Case Report: Primary Ewing Sarcoma of the Penis
Soumen Das, Siddhartha Shankar Mishra, Kamalesh Rakshit, Rahul Agarwal
Indian Journal of Surgical Oncology.2023; 14(3): 752. CrossRef
Retroperitoneal blue cell round tumor (Ewing sarcoma in a 35 years old male)- case report
Fatema Nabeel Nedham, Veena Nagaraj, Abdulla Darwish, Thamer Abduljabbar Al-Abbasi
International Journal of Surgery Case Reports.2022; 94: 107045. CrossRef
Abdominal Wall Extraskeletal Ewing's Sarcoma in an 8-Year-Old Child
Gowri Shankar, Vinay Kumar Konamme
Journal of Indian Association of Pediatric Surgeons.2022; 27(6): 771. CrossRef
Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Adil Abbas, Mohammed N.S. Alaa
Current Cancer Therapy Reviews.2021; 17(2): 107. CrossRef
Extraskeletal Ewing’s sarcoma/primitive neuroectodermal tumor of the mediastinum: Significant response to chemoradiotherapy
MIN LIU, BAILONG LIU, LIHUA DONG, TAO HAN, LEI ZHANG
Oncology Letters.2015; 9(2): 626. CrossRef
Retroperitoneal Extraskeletal Ewing's Sarcoma
Si Hyung Lee, Byung Ik Jang
The Korean Journal of Gastroenterology.2013; 62(4): 253. CrossRef
Scapular bone destruction: do not forget to think of tuberculosis in endemic areas
Barun Kumar Sharma, Varun Kumar Singh, Kumar Nishant, Deepak Das
BMJ Case Reports.2013; : bcr2013200051. CrossRef
Primary Ewing’s Sarcoma of Penis – A Rare Case Report
Prashant Sharma, Hemang Bakshi, Yogen Chheda, Surender Beniwal
Indian Journal of Surgical Oncology.2011; 2(4): 332. CrossRef
High Efficacy of Preoperative Low-Dose Radiotherapy with Sanazole (AK-2123) for Extraskeletal Ewing's Sarcoma: A Case Report
Tomoya Sakabe, Hiroaki Murata, Eiichi Konishi, Kazutaka Koto, Naoyuki Horie, Takaaki Matsui, Yasushi Sawai, Hideya Yamazaki, Tsutomu V. Kagiya, Toshikazu Kubo
Sarcoma.2011; 2011: 1. CrossRef
A Case of Cervical Ewing Sarcoma with Pulmonary Metastasis
Jong Chul Hong, Jae Hoon Lee, Seo Hee Rha, Heon Soo Park
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2010; 53(7): 441. CrossRef

10,135 View
46 Download
11 Crossref

Original Article

A Phase II Study of Genexol(R) (paclitaxel) in Metastatic Breast Cancer: Joo Young Jung, Hyun Chul Jeong, Sung Soo Yoon, Jae Hoon Lee, Jun Seok Kim, Hyo Jin Kim, Ki Hyun Kim, Jun O Park, Won Seop Lee, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2001;33(6):451-457. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.451

Abstract PDF

PURPOSE
Paclitaxel is a very effective agent in the treatment of breast cancer. Samyang Corporation has developed its own process to produce paclitaxel in a large volume using plant cell culture technology. To evaluate the efficacy and safety of Genexol(R) in patients with metastatic breast cancer who have failed to respond to standard therapy, we performed a prospective, multi- center phase II clinical trial.
MATERIALS AND METHODS
Patients with metastatic breast cancer were included in this study. Enrollees were required to have histologically confirmed breast cancer with bidimensionally measurable metastatic disease. Genexol(R) was administered at 175 mg/m2 as a 3-hour intravenous infusion every 3 weeks. All patients were premedicated with hydrocortisone, pheniramine maleate, and H2 blocker 30 minutes prior to paclitaxel. We planned to administer at least 4 courses of paclitaxel unless there was disease progression or unacceptable toxicity and to continue treatment up to a total of 6 courses in cases of objective response following 4 courses.
RESULTS
The median duration of follow-up was 8.9 (2.07~13.7) months. Forty-five patients were registered and 43 were eligible. The performance status of patients was ECOG 0~1 in 39 patients (90.7%) and 2 in 4 (9.3%). The location of metastases at the start of the study were the lung (15 patients), liver (8 patients), lymph nodes (22 patients), and other (7 patients). Among the 40 evaluable patients, 15 patients obtained partial responses (PRs) (37.5%, 95% CI: 22.5~52.5%). The median duration of response was 11.67 (4.1~11.7) months and the median time to progression was 7.73 (2.8~11.7) months. The median survival time was not reached at 13.7 months, and the overall survival rate at 13.7 months was 70.1%. The hematologic toxicity was primarily neutropenia with grade 3 or 4 in 10 patients (23.3%). The grade 3 or 4 non-hematologic toxicities included alopecia (17, 39.5%), myalgia (2, 4.7%), neuropathy (2, 4.7%), and pruritus (1, 2.3%). Mild hypersensitivity reaction was observed in 2 patients, although it did not cause withdrawal of the test drug.
CONCLUSION
The results suggest that the Genexol injection is an effective anticancer formulation for the treatment of metastatic breast cancer and toxicity is acceptable.

Citations

Citations to this article as recorded by

Current status of nanomedicine in the chemotherapy of breast cancer
A. I. Fraguas-Sánchez, C. Martín-Sabroso, A. Fernández-Carballido, A. I. Torres-Suárez
Cancer Chemotherapy and Pharmacology.2019; 84(4): 689. CrossRef
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
H. Chang, S.Y. Rha, H.-C. Jeung, C.-K. Im, J.B. Ahn, W.S. Kwon, N.C. Yoo, J.K. Roh, H.C. Chung
Annals of Oncology.2009; 20(2): 272. CrossRef

5,378 View
43 Download
2 Crossref

First
Prev
Page of 1
Next
Last

Search